{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:16:01Z","timestamp":1779297361967,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008126","name":"Jeju National University Hospital","doi-asserted-by":"publisher","award":["JNUH2019"],"award-info":[{"award-number":["JNUH2019"]}],"id":[{"id":"10.13039\/501100008126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81764-6","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T02:28:25Z","timestamp":1735352905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of PD-L1 positivity with Epstein Barr virus infection and microsatellite instability in gastric carcinomas with lymphoid stroma"],"prefix":"10.1038","volume":"14","author":[{"given":"Sun Mi","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjoo","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"81764_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research, N","year":"2014","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209. https:\/\/doi.org\/10.1038\/nature13480 (2014).","journal-title":"Nature"},{"key":"81764_CR2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10120-020-01095-z","volume":"23","author":"E Ignatova","year":"2020","unstructured":"Ignatova, E. et al. Epstein\u2013Barr virus-associated gastric cancer: Disease that requires special approach. Gastric Cancer. 23, 951\u2013960. https:\/\/doi.org\/10.1007\/s10120-020-01095-z (2020).","journal-title":"Gastric Cancer"},{"key":"81764_CR3","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1158\/0008-5472.CAN-11-3919","volume":"72","author":"A Kaneda","year":"2012","unstructured":"Kaneda, A., Matsusaka, K., Aburatani, H. & Fukayama, M. Epstein\u2013Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res. 72, 3445\u20133450. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3919 (2012).","journal-title":"Cancer Res."},{"key":"81764_CR4","doi-asserted-by":"publisher","first-page":"E5199","DOI":"10.1073\/pnas.1503806112","volume":"112","author":"A Saha","year":"2015","unstructured":"Saha, A., Jha, H. C., Upadhyay, S. K. & Robertson, E. S. Epigenetic silencing of tumor suppressor genes during in vitro Epstein\u2013Barr virus infection. Proc. Natl. Acad. Sci. U S A. 112, E5199\u20135207. https:\/\/doi.org\/10.1073\/pnas.1503806112 (2015).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"81764_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/labinvest.3700707","volume":"88","author":"GH Kang","year":"2008","unstructured":"Kang, G. H. et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab. Invest. 88, 161\u2013170. https:\/\/doi.org\/10.1038\/labinvest.3700707 (2008).","journal-title":"Lab. Invest."},{"key":"81764_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jmv.2152","volume":"66","author":"Y Hoshikawa","year":"2002","unstructured":"Hoshikawa, Y. et al. Evidence of lytic infection of Epstein\u2013Barr virus (EBV) in EBV-positive gastric carcinoma. J. Med. Virol. 66, 351\u2013359. https:\/\/doi.org\/10.1002\/jmv.2152 (2002).","journal-title":"J. Med. Virol."},{"key":"81764_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/s0046-8177(96)90133-1","volume":"27","author":"ML Gulley","year":"1996","unstructured":"Gulley, M. L., Pulitzer, D. R., Eagan, P. A. & Schneider, B. G. Epstein\u2013Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum. Pathol. 27, 20\u201327. https:\/\/doi.org\/10.1016\/s0046-8177(96)90133-1 (1996).","journal-title":"Hum. Pathol."},{"key":"81764_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3748\/wjg.v11.i5.629","volume":"11","author":"B Luo","year":"2005","unstructured":"Luo, B. et al. Expression of EpsteinBarr virus genes in EBV-associated gastric carcinomas. World J. Gastroenterol. 11, 629\u2013633. https:\/\/doi.org\/10.3748\/wjg.v11.i5.629 (2005).","journal-title":"World J. Gastroenterol."},{"key":"81764_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3892\/ijo.2015.2856","volume":"46","author":"A Shinozaki-Ushiku","year":"2015","unstructured":"Shinozaki-Ushiku, A., Kunita, A. & Fukayama, M. Update on Epstein\u2013Barr virus and gastric cancer (review). Int. J. Oncol. 46, 1421\u20131434. https:\/\/doi.org\/10.3892\/ijo.2015.2856 (2015).","journal-title":"Int. J. Oncol."},{"key":"81764_CR10","unstructured":"Carneiro, F., Fukayama, M., Grabsch, H. I. & Yasui, W. IACR Press. In WHO Classification of Digestive System Tumours (ed WHO Classification of Tumours Editorial Board) 85\u201395 (2019)."},{"key":"81764_CR11","first-page":"1250","volume":"143","author":"M Tokunaga","year":"1993","unstructured":"Tokunaga, M. et al. Epstein\u2013Barr virus in gastric carcinoma. Am. J. Pathol. 143, 1250\u20131254 (1993).","journal-title":"Am. J. Pathol."},{"key":"81764_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.prp.2011.07.004","volume":"207","author":"M Fukayama","year":"2011","unstructured":"Fukayama, M. & Ushiku, T. Epstein\u2013Barr virus-associated gastric carcinoma. Pathol. Res. Pract. 207, 529\u2013537. https:\/\/doi.org\/10.1016\/j.prp.2011.07.004 (2011).","journal-title":"Pathol. Res. Pract."},{"key":"81764_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/01.MP.0000076980.73826.C0","volume":"16","author":"KL Grogg","year":"2003","unstructured":"Grogg, K. L., Lohse, C. M., Pankratz, V. S., Halling, K. C. & Smyrk, T. C. Lymphocyte-rich gastric cancer: Associations with Epstein\u2013Barr virus, microsatellite instability, histology, and survival. Mod. Pathol. 16, 641\u2013651. https:\/\/doi.org\/10.1097\/01.MP.0000076980.73826.C0 (2003).","journal-title":"Mod. Pathol."},{"key":"81764_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24, 1449\u20131458. https:\/\/doi.org\/10.1038\/s41591-018-0101-z (2018).","journal-title":"Nat. Med."},{"key":"81764_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-019-0743-4","volume":"12","author":"P Gao","year":"2019","unstructured":"Gao, P. et al. Immune checkpoint inhibitors in the treatment of virus-associated cancers. J. Hematol. Oncol. 12, 58. https:\/\/doi.org\/10.1186\/s13045-019-0743-4 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"81764_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andre","year":"2023","unstructured":"Andre, T. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study. J. Clin. Oncol. 41, 255\u2013265. https:\/\/doi.org\/10.1200\/JCO.22.00686 (2023).","journal-title":"J. Clin. Oncol."},{"key":"81764_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12, 252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"81764_CR18","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690 (2012).","journal-title":"N. Engl. J. Med."},{"key":"81764_CR19","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465. https:\/\/doi.org\/10.1056\/NEJMoa1200694 (2012).","journal-title":"N. Engl. J. Med."},{"key":"81764_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa1305133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"81764_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey, J. D. & Zhang, B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 23, 39. https:\/\/doi.org\/10.1208\/s12248-021-00574-0 (2021).","journal-title":"AAPS J."},{"key":"81764_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"81764_CR23","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865 (2018).","journal-title":"N. Engl. J. Med."},{"key":"81764_CR24","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs, C. S. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4, e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013 (2018).","journal-title":"JAMA Oncol."},{"key":"81764_CR25","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5 (2017).","journal-title":"Lancet"},{"key":"81764_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234\u2013247. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6 (2022).","journal-title":"Lancet Oncol."},{"key":"81764_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","volume":"20","author":"A Kawazoe","year":"2017","unstructured":"Kawazoe, A. et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein\u2013Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 20, 407\u2013415. https:\/\/doi.org\/10.1007\/s10120-016-0631-3 (2017).","journal-title":"Gastric Cancer"},{"key":"81764_CR28","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1097\/PAS.0000000000000698","volume":"40","author":"C Ma","year":"2016","unstructured":"Ma, C. et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein\u2013Barr virus or microsatellite instability. Am. J. Surg. Pathol. 40, 1496\u20131506. https:\/\/doi.org\/10.1097\/PAS.0000000000000698 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"81764_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15384047.2022.2038002","volume":"23","author":"T Yoshida","year":"2022","unstructured":"Yoshida, T. et al. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. Cancer Biol. Ther. 23, 191\u2013200. https:\/\/doi.org\/10.1080\/15384047.2022.2038002 (2022).","journal-title":"Cancer Biol. Ther."},{"key":"81764_CR30","doi-asserted-by":"publisher","unstructured":"Fang, W. L. et al. The clinicopathological features and genetic alterations in Epstein\u2013Barr virus-associated gastric cancer patients after curative surgery. Cancers (Basel). 12 https:\/\/doi.org\/10.3390\/cancers12061517 (2020).","DOI":"10.3390\/cancers12061517"},{"key":"81764_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/PAI.0000000000000264","volume":"25","author":"M Mathiak","year":"2017","unstructured":"Mathiak, M. et al. Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: Urgent need for standardization. Appl. Immunohistochem. Mol. Morphol. 25, 12\u201324. https:\/\/doi.org\/10.1097\/PAI.0000000000000264 (2017).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"81764_CR32","doi-asserted-by":"publisher","unstructured":"Lim, H. et al. Features of gastric carcinoma with lymphoid stroma associated With Epstein\u2013Barr virus. Clin. Gastroenterol. Hepatol. 13, 1738\u20131744 e1732 (2015). https:\/\/doi.org\/10.1016\/j.cgh.2015.04.015","DOI":"10.1016\/j.cgh.2015.04.015"},{"key":"81764_CR33","first-page":"469","volume":"139","author":"D Shibata","year":"1991","unstructured":"Shibata, D. et al. Association of Epstein\u2013Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am. J. Pathol. 139, 469\u2013474 (1991).","journal-title":"Am. J. Pathol."},{"key":"81764_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s101200050003","volume":"1","author":"M Fukayama","year":"1998","unstructured":"Fukayama, M., Chong, J. M. & Kaizaki, Y. Epstein\u2013Barr virus and gastric carcinoma. Gastric Cancer. 1, 104\u2013114. https:\/\/doi.org\/10.1007\/s101200050003 (1998).","journal-title":"Gastric Cancer"},{"key":"81764_CR35","doi-asserted-by":"publisher","first-page":"712760","DOI":"10.3389\/fonc.2021.712760","volume":"11","author":"WL Guan","year":"2021","unstructured":"Guan, W. L. et al. The impact of mismatch repair status on prognosis of patients with gastric cancer: A multicenter analysis. Front. Oncol. 11, 712760. https:\/\/doi.org\/10.3389\/fonc.2021.712760 (2021).","journal-title":"Front. Oncol."},{"key":"81764_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bjs.10663","volume":"105","author":"K Polom","year":"2018","unstructured":"Polom, K. et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br. J. Surg. 105, 159\u2013167. https:\/\/doi.org\/10.1002\/bjs.10663 (2018).","journal-title":"Br. J. Surg."},{"key":"81764_CR37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s10120-015-0524-x","volume":"19","author":"BH Min","year":"2016","unstructured":"Min, B. H. et al. Epstein\u2013Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma. Gastric Cancer. 19, 852\u2013859. https:\/\/doi.org\/10.1007\/s10120-015-0524-x (2016).","journal-title":"Gastric Cancer"},{"key":"81764_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/PAI.0b013e31821c821c","volume":"20","author":"PL Kunz","year":"2012","unstructured":"Kunz, P. L. et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: Clinicopathologic analysis with proposed approach to HER2 assessment. Appl. Immunohistochem. Mol. Morphol. 20, 13\u201324. https:\/\/doi.org\/10.1097\/PAI.0b013e31821c821c (2012).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"81764_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/jclinpath-2012-200774","volume":"65","author":"C Gomez-Martin","year":"2012","unstructured":"Gomez-Martin, C. et al. HER2\/neu testing for anti-HER2-based therapies in patients with unresectable and\/or metastatic gastric cancer. J. Clin. Pathol. 65, 751\u2013757. https:\/\/doi.org\/10.1136\/jclinpath-2012-200774 (2012).","journal-title":"J. Clin. Pathol."},{"key":"81764_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mdi064","volume":"16","author":"M Tanner","year":"2005","unstructured":"Tanner, M. et al. Amplification of HER-2 in gastric carcinoma: Association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273\u2013278. https:\/\/doi.org\/10.1093\/annonc\/mdi064 (2005).","journal-title":"Ann. Oncol."},{"key":"81764_CR41","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.ccr-1122-3","volume":"10","author":"HS Lee","year":"2004","unstructured":"Lee, H. S., Chang, M. S., Yang, H. K., Lee, B. L. & Kim, W. H. Epstein\u2013Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein\u2013Barr virus-negative carcinoma. Clin. Cancer Res. 10, 1698\u20131705. https:\/\/doi.org\/10.1158\/1078-0432.ccr-1122-3 (2004).","journal-title":"Clin. Cancer Res."},{"key":"81764_CR42","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.3748\/wjg.v18.i45.6577","volume":"18","author":"Y Sukawa","year":"2012","unstructured":"Sukawa, Y. et al. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J. Gastroenterol. 18, 6577\u20136586. https:\/\/doi.org\/10.3748\/wjg.v18.i45.6577 (2012).","journal-title":"World J. Gastroenterol."},{"key":"81764_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.humpath.2019.10.008","volume":"94","author":"N Setia","year":"2019","unstructured":"Setia, N., Ahn, S., Han, H. S., Park, D. Y. & Lauwers, G. Y. Predictive value of WHO classification for PD-L1 and Her2\/Neu expression and distinct associations with protein expression based classification in gastric carcinoma. Hum. Pathol. 94, 64\u201370. https:\/\/doi.org\/10.1016\/j.humpath.2019.10.008 (2019).","journal-title":"Hum. Pathol."},{"key":"81764_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.21037\/jgo-21-47","volume":"12","author":"H Huang","year":"2021","unstructured":"Huang, H., Wang, Z., Li, Y., Zhao, Q. & Niu, Z. Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. J. Gastrointest. Oncol. 12, 377\u2013387. https:\/\/doi.org\/10.21037\/jgo-21-47 (2021).","journal-title":"J. Gastrointest. Oncol."},{"key":"81764_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12672-022-00479-0","volume":"13","author":"A Lima","year":"2022","unstructured":"Lima, A., Sousa, H., Medeiros, R., Nobre, A. & Machado, M. PD-L1 expression in EBV associated gastric cancer: A systematic review and meta-analysis. Discov Oncol. 13, 19. https:\/\/doi.org\/10.1007\/s12672-022-00479-0 (2022).","journal-title":"Discov Oncol."},{"key":"81764_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.humpath.2016.02.007","volume":"53","author":"M Dong","year":"2016","unstructured":"Dong, M. et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein\u2013Barr virus-associated gastric carcinoma. Hum. Pathol. 53, 25\u201334. https:\/\/doi.org\/10.1016\/j.humpath.2016.02.007 (2016).","journal-title":"Hum. Pathol."},{"key":"81764_CR47","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/bjc.2017.369","volume":"117","author":"AN Seo","year":"2017","unstructured":"Seo, A. N. et al. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein\u2013Barr virus-associated gastric cancer. Br. J. Cancer. 117, 1753\u20131760. https:\/\/doi.org\/10.1038\/bjc.2017.369 (2017).","journal-title":"Br. J. Cancer"},{"key":"81764_CR48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/PAS.0000000000001018","volume":"42","author":"E Hissong","year":"2018","unstructured":"Hissong, E. et al. Gastric carcinomas with lymphoid stroma: An evaluation of the histopathologic and molecular features. Am. J. Surg. Pathol. 42, 453\u2013462. https:\/\/doi.org\/10.1097\/PAS.0000000000001018 (2018).","journal-title":"Am. J. Surg. Pathol."},{"key":"81764_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 392, 123\u2013133. https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1 (2018).","journal-title":"Lancet"},{"key":"81764_CR50","doi-asserted-by":"publisher","first-page":"e16111","DOI":"10.1200\/JCO.2021.39.15_suppl.e16111","volume":"39","author":"T Kennedy","year":"2021","unstructured":"Kennedy, T. et al. Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial (NCT03257163). J. Clin. Oncol. 39, e16111\u2013e16111. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e16111 (2021).","journal-title":"J. Clin. Oncol."},{"key":"81764_CR51","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/DDDT.S75152","volume":"9","author":"Y Qing","year":"2015","unstructured":"Qing, Y. et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des. Devel Ther. 9, 901\u2013909. https:\/\/doi.org\/10.2147\/DDDT.S75152 (2015).","journal-title":"Drug Des. Devel Ther."},{"key":"81764_CR52","unstructured":"Ajani, J. A., Sano, I. H., Gaspar, T., Erasmus, L. E. & Tang, J. J. LH, et al. AJCC Cancer Staging Manual 8th edn (Springer, 2017)."},{"key":"81764_CR53","first-page":"5248","volume":"58","author":"CR Boland","year":"1998","unstructured":"Boland, C. R. et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248\u20135257 (1998).","journal-title":"Cancer Res."},{"key":"81764_CR54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S1525-1578(10)60611-3","volume":"2","author":"KD Berg","year":"2000","unstructured":"Berg, K. D. et al. Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction. J. Mol. Diagn. 2, 20\u201328. https:\/\/doi.org\/10.1016\/S1525-1578(10)60611-3 (2000).","journal-title":"J. Mol. Diagn."},{"key":"81764_CR55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann, M. et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52, 797\u2013805. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03028.x (2008).","journal-title":"Histopathology"},{"key":"81764_CR56","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J Ruschoff","year":"2012","unstructured":"Ruschoff, J. et al. HER2 testing in gastric cancer: A practical approach. Mod. Pathol. 25, 637\u2013650. https:\/\/doi.org\/10.1038\/modpathol.2011.198 (2012).","journal-title":"Mod. Pathol."},{"key":"81764_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","volume":"53","author":"EC Paver","year":"2021","unstructured":"Paver, E. C. et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: A guide to immunohistochemistry implementation and interpretation. Pathology 53, 141\u2013156. https:\/\/doi.org\/10.1016\/j.pathol.2020.10.007 (2021).","journal-title":"Pathology"},{"key":"81764_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/OP.22.00226","volume":"19","author":"S Patruni","year":"2023","unstructured":"Patruni, S., Fayyaz, F., Bien, J., Phillip, T. & King, D. A. Immunotherapy in the management of esophagogastric cancer: A practical review. JCO Oncol. Pract. 19, 107\u2013115. https:\/\/doi.org\/10.1200\/OP.22.00226 (2023).","journal-title":"JCO Oncol. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81764-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T16:04:13Z","timestamp":1735401853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81764-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81764"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81764-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Jeju National University Hospital (IRB File No. JEJUNUH 2022-01-016). The informed written consent was also obtained from the subjects involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30932"}}